

Alessandro Capucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11592402/publications.pdf>

Version: 2024-02-01

81
papers

10,891
citations

100601

38
h-index

78623

77
g-index

81
all docs

81
docs citations

81
times ranked

8652
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal Association of Atrial Fibrillation With Cardiac Implanted Electronic Device Detected Heart Failure Status. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 182-193.	1.3	4
2	Association between implantable defibrillator-detected sleep apnea and atrial fibrillation: the DASAP-HF study. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, , .	0.8	2
3	“Pill in the Pocket” Antiarrhythmic Drugs for Orally Administered Pharmacologic Cardioversion of Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2021, 140, 55-61.	0.7	9
4	Device-Detected Atrial Fibrillation Before and After Hospitalisation for Noncardiac Surgery or Medical Illness: Insights From ASSERT. <i>Canadian Journal of Cardiology</i> , 2021, 37, 803-809.	0.8	6
5	Is delayed cardioversion the better approach in recent-onset atrial fibrillation? No. <i>Internal and Emergency Medicine</i> , 2020, 15, 5-7.	1.0	8
6	Clinical classification and the subclinical atrial fibrillation challenge: a position paper of the European Cardiac Arrhythmia Society. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 59, 495-507.	0.6	6
7	Atrial signal amplitude predicts atrial high-rate episodes in implantable cardioverter defibrillator patients: Insights from a large database of remote monitoring transmissions. <i>Journal of Arrhythmia</i> , 2020, 36, 353-362.	0.5	3
8	Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. <i>Europace</i> , 2019, 21, 1764-1775.	0.7	20
9	Are Atrial High-Rate Episodes Associated With Increased Risk of Ventricular Arrhythmias and Mortality?. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 1197-1208.	1.3	17
10	Outcomes after sudden cardiac arrest in sports centres with and without on-site external defibrillators. <i>Heart</i> , 2018, 104, 1344-1349.	1.2	32
11	Emerging pharmacotherapies for the treatment of atrial fibrillation. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 25-36.	1.0	13
12	Physical Activity Measured by Implanted Devices Predicts Atrial Arrhythmias and Patient Outcome: Results of IMPLANTED (Italian Multicentre Observational Registry on Patients With Implantable) <i>Tj ETQq0 0 0 rgBT 10verlock 24 Tf 50 20</i>	1.0	24
13	Does the CHA ₂ DS ₂ -VASc score reliably predict atrial arrhythmias? Analysis of a nationwide database of remote monitoring data transmitted daily from cardiac implantable electronic devices. <i>Heart Rhythm</i> , 2018, 15, 971-979.	0.3	26
14	The influence of progression of atrial fibrillation on quality of life: a report from the Euro Heart Survey. <i>Europace</i> , 2018, 20, 929-934.	0.7	30
15	Stroke type and severity in patients with subclinical atrial fibrillation: An analysis from the Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial (ASSERT). <i>American Heart Journal</i> , 2018, 201, 160-163.	1.2	26
16	Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey). <i>American Journal of Cardiology</i> , 2018, 122, 578-583.	0.7	12
17	Progression of Device-Detected Subclinical Atrial Fibrillation and the Risk of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2603-2611.	1.2	91
18	Can we predict new AF occurrence in single-chamber ICD patients? Insights from an observational investigation. <i>International Journal of Cardiology</i> , 2017, 230, 275-280.	0.8	8

#	ARTICLE	IF	CITATIONS
19	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	1.2	244
20	Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. <i>European Heart Journal</i> , 2017, 38, 1339-1344.	1.0	428
21	Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey. <i>Europace</i> , 2017, 19, 1922-1929.	0.7	27
22	Community-based automated external defibrillator only resuscitation for out-of-hospital cardiac arrest patients. <i>American Heart Journal</i> , 2016, 172, 192-200.	1.2	36
23	Cardioembolism and takotsubo syndrome: A case report. <i>International Journal of Cardiology</i> , 2016, 211, 68-70.	0.8	3
24	Remote monitoring improves outcome after ICD implantation: the clinical efficacy in the management of heart failure (EFFECT) study. <i>Europace</i> , 2015, 17, 1267-1275.	0.7	56
25	New antiarrhythmic drugs for atrial fibrillation. <i>Future Cardiology</i> , 2015, 11, 705-717.	0.5	1
26	Response to Letter Regarding Article "Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events". <i>Circulation</i> , 2015, 131, e337-8.	1.6	0
27	Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1067-1075.	0.6	8
28	Out-of-hospital cardiac arrest and public access defibrillation. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 624-625.	0.6	0
29	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. <i>Circulation</i> , 2014, 129, 2094-2099.	1.6	579
30	Efficacy and Safety of Dronedaron in Patients Previously Treated With Other Antiarrhythmic Agents. <i>Clinical Cardiology</i> , 2014, 37, 717-724.	0.7	7
31	Silent Atrial Fibrillation: A Critical Review. <i>Journal of Atrial Fibrillation</i> , 2014, 7, 1138.	0.5	13
32	Ethnic Differences in Atrial Fibrillation Identified Using Implanted Cardiac Devices. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 381-387.	0.8	55
33	Effects of Dronedaron Started Rapidly After Amiodaron Discontinuation. <i>Clinical Cardiology</i> , 2013, 36, 88-95.	0.7	7
34	Improving Thromboprophylaxis Using Atrial Fibrillation Diagnostic Capabilities in Implantable Cardioverter-Defibrillators. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 182-188.	0.9	33
35	Atrial overdrive pacing to prevent atrial fibrillation: Insights from ASSERT. <i>Heart Rhythm</i> , 2012, 9, 1667-1673.	0.3	54
36	Safety of Flecainide. <i>Drug Safety</i> , 2012, 35, 273-289.	1.4	29

#	ARTICLE	IF	CITATIONS
37	Subclinical Atrial Fibrillation and the Risk of Stroke. <i>New England Journal of Medicine</i> , 2012, 366, 120-129.	13.9	1,751
38	Implanted Devices and Atrial Fibrillation. , 2012, , .		1
39	Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 462-472.	0.8	10
40	Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death. <i>Circulation</i> , 2011, 124, 2649-2660.	1.6	45
41	A Randomized Active-Controlled Study Comparing the Efficacy and Safety of Vernakalant to Amiodarone in Recent-Onset Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2011, 57, 313-321.	1.2	239
42	Antiarrhythmic drugs for atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1201-1215.	0.9	4
43	Vernakalant hydrochloride in the treatment of atrial fibrillation: a review of the latest clinical evidence. <i>Clinical Investigation</i> , 2011, 1, 579-588.	0.0	1
44	Public access defibrillation: new developments for mass implementation. <i>Heart</i> , 2011, 97, 1528-1532.	1.2	8
45	Improving Stroke Risk Stratification Using the CHADS ₂ and CHA ₂ DS ₂ -VASc Risk Scores in Patients With Paroxysmal Atrial Fibrillation by Continuous Arrhythmia Burden Monitoring. <i>Stroke</i> , 2011, 42, 1768-1770.	1.0	176
46	Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. <i>Europace</i> , 2011, 13, 161-173.	0.7	140
47	Role of sotalol in rhythm control of atrial fibrillation. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 391-407.	0.2	0
48	Pharmacologic Conversion of Atrial Fibrillation and Atrial Flutter. <i>Cardiac Electrophysiology Clinics</i> , 2010, 2, 393-407.	0.7	2
49	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2010, 12, 1360-1420.	0.7	1,360
50	Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during 'pill-in-the-pocket' treatment. <i>Heart</i> , 2010, 96, 546-549.	1.2	49
51	Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 241-248.	0.8	341
52	Atrial Fibrillation and Heart Failure in Cardiology Practice: Reciprocal Impact and Combined Management From the Perspective of Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1690-1698.	1.2	98
53	Autonomic trigger patterns and anti-arrhythmic treatment of paroxysmal atrial fibrillation: data from the Euro Heart Survey. <i>European Heart Journal</i> , 2008, 29, 632-639.	1.0	100
54	Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?. <i>European Heart Journal</i> , 2008, 29, 915-922.	1.0	109

#	ARTICLE	IF	CITATIONS
55	Dronedaronone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. <i>New England Journal of Medicine</i> , 2007, 357, 987-999.	13.9	597
56	Atrial fibrillation in the "real world": undecided issues. <i>Country Review Ukraine</i> , 2007, 9, 1122-1128.	0.8	2
57	Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. <i>The Euro Heart Survey on Atrial Fibrillation. American Heart Journal</i> , 2007, 153, 1006-1012.	1.2	197
58	Rate control in patients with pacemaker affected by brady-tachy form of sick sinus syndrome. <i>American Heart Journal</i> , 2007, 154, 193-200.	1.2	10
59	Duration of P-Wave Is Associated with Atrial Fibrillation Hospitalizations in Patients with Atrial Fibrillation and Paced for Bradycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007, 30, 961-969.	0.5	9
60	ASymptomatic atrial fibrillation and Stroke Evaluation in pacemaker patients and the atrial fibrillation Reduction atrial pacing Trial (ASSERT). <i>American Heart Journal</i> , 2006, 152, 442-447.	1.2	117
61	Reduced Peripheral Skeletal Muscle Mass and Abnormal Reflex Physiology in Chronic Heart Failure. <i>Circulation</i> , 2006, 114, 126-134.	1.6	135
62	Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. <i>European Heart Journal</i> , 2006, 27, 3018-3026.	1.0	353
63	Atrial fibrillation management: a prospective survey in ESC Member Countries. <i>European Heart Journal</i> , 2005, 26, 2422-2434.	1.0	770
64	Monitored Atrial Fibrillation Duration Predicts Arterial Embolic Events in Patients Suffering From Bradycardia and Atrial Fibrillation Implanted With Antitachycardia Pacemakers. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1913-1920.	1.2	375
65	ESC-ERC recommendations for the use of automated external defibrillators (AEDs) in Europe. <i>European Heart Journal</i> , 2004, 25, 437-445.	1.0	78
66	Atrial Tachyarrhythmia Recurrence Temporal Patterns in Bradycardia Patients Implanted with Antitachycardia Pacemakers. <i>Journal of Cardiovascular Electrophysiology</i> , 2004, 15, 44-51.	0.8	25
67	Policy Statement. <i>Resuscitation</i> , 2004, 60, 245-252.	1.3	29
68	Dronedaronone for prevention of atrial fibrillation: A dose-ranging study. <i>European Heart Journal</i> , 2003, 24, 1481-1487.	1.0	295
69	Tripling Survival From Sudden Cardiac Arrest Via Early Defibrillation Without Traditional Education in Cardiopulmonary Resuscitation. <i>Circulation</i> , 2002, 106, 1065-1070.	1.6	279
70	Muscle Ergoreceptor Overactivity Reflects Deterioration in Clinical Status and Cardiorespiratory Reflex Control in Chronic Heart Failure. <i>Circulation</i> , 2001, 104, 2324-2330.	1.6	208
71	Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm. <i>International Journal of Cardiology</i> , 1999, 68, 187-196.	0.8	64
72	Favorable effects of flecainide in transvenous internal cardioversion of atrial fibrillation. <i>Journal of the American College of Cardiology</i> , 1999, 33, 333-341.	1.2	57

#	ARTICLE	IF	CITATIONS
73	A neural link to explain the "œmuscle hypothesis" of exercise intolerance in chronic heart failure. American Heart Journal, 1999, 137, 1050-1056.	1.2	126
74	The role of oral 1C antiarrhythmic drugs in terminating atrial fibrillation. Current Opinion in Cardiology, 1999, 14, 4.	0.8	35
75	Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure. American Journal of Cardiology, 1998, 82, 338-344.	0.7	60
76	Clinical Pharmacology of Antiarrhythmic Drugs. Drugs and Aging, 1998, 13, 51-70.	1.3	9
77	Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral loading dose of propafenone: comparison of two regimens. International Journal of Cardiology, 1997, 58, 55-61.	0.8	69
78	Propafenone for Conversion of Recent-Onset Atrial Fibrillation. Chest, 1995, 108, 355-358.	0.4	106
79	Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. American Journal of Cardiology, 1994, 74, 503-505.	0.7	175
80	A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. International Journal of Cardiology, 1994, 43, 305-313.	0.8	121
81	Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. American Journal of Cardiology, 1992, 70, 69-72.	0.7	239